Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

US: Bill to prohibit reverse payments introduced in the Senate (Patent Docs) (Law360) (Patent Prospector)

AndroGel (Testosterone) – US: FTC sues Solvay for paying Watson and Par Pharma to delay launch of generic AndroGel: (Patent Baristas) (SmartBrief) (FDA Law Blog) (IP Watchdog) (Law360) (Patent Prospector) (GenericsWeb)

Brazil, India challenge other WTO members right to block legitimate shipping of generic medicines on basis of potential IPR conflicts in transit country (Intellectual Property Watch) (Spicy IP)

WHO seeks $147 billion for R&D into neglected diseases – can it be done for less? (IP finance)

Pharmaceutical Technology article on barriers to entry for generic pharma companies based in emerging economies (Afro-IP)

The effects of IP protection on agricultural research: Patents are not the problem – response to Nature Biotechnology article ‘Patents Versus Patenting: Implications of Intellectual Property Protection for Biological Research’ (Patent Docs)

SPC seminar – a brief report (The SPC Blog) (The SPC Blog)

Ruminations on the Pfizer-Wyeth merger (IP finance)

Brazil, India challenge other WTO members right to block legitimate shipping of generic medicines on basis of potential IPR conflicts in transit country (Intellectual Property Watch) (Spicy IP)

EU: The need for IP governance in the pharma industry: EC preliminary report on ‘Pharmaceutical Sector Inquiry’ (IPEG)

EU to post comments on drug sector antitrust probe (Law360)

EU pharma sector inquiry – the Intellectual Property Institute response (IPKat)

India: Patent Office investigation into ‘negligent’ pharma patent grants (Spicy IP)

US: Has change come to biology? Stem cell research under Obama (Ars Technica)

US: Oxford Gene Technology settles legal action with Bioarray Solutions over patents covering use of microassays for detection of DNA sequence variations (Patent Docs)

US: BPAI affirms rejection of claims to an isolated protein over prior art disclosing nucleic acid encoding the protein: Ex parte Chuang (not precedential) (Patent Docs) (Post-Grant)

US: Supreme petitioned to grant certiorari in two cases important to biotech patenting: In re Bilski and Aventis Pharma SA v Amphastar Pharmaceuticals (Patent Docs)

US: Bill to prohibit reverse payments introduced in the Senate (Patent Docs) (Law360) (Patent Prospector)

US: Applied Genetic Technologies sues Genzyme claiming IP misappropriation as gene therapy pact falls apart (Law360)

US: Novartis files amicus brief supporting Prometheus and the patentability of personalised medicine claims: Prometheus v Mayo (Holman’s Biotech IP Blog)

US: Applying In re Bilski to EXACT Sciences’ diagnostic method claims (Patent Docs)

AndroGel (Testosterone) – US: FTC sues Solvay for paying Watson and Par Pharma to delay launch of generic AndroGel: (Patent Baristas) (SmartBrief) (FDA Law Blog) (IP Watchdog) (Law360) (Patent Prospector) (GenericsWeb)

AndroGel (Testosterone) – US: Three classes of AndroGel buyers file separate actions claiming patent settlements over the drug thwarted competition (Law360)

Combivent (Ipratropium, Salbutamol) – UK: Speculative patents with added M A D: Laboratorios Almirall SA v Boehringer Ingelheim International GmbH (IPKat)

Coversyl (Perindopril) – South Africa: Court of the Commissioner of Patents hears Servier’s application for interim interdict preventing Cipla from selling generic Coversyl 2-4 Feb: Les Laboratoires Servier et al v Cipla Medpro et al (Afro-IP) (Afro-IP)

Doryx (Doxycycline) – US: Warner Chilcott files new lawsuit, this time against Actavis, for infringement of Doryx patent (SmartBrief)

Evista (Raloxifene) – US: Eli Lilly sues InvaGen Pharmaceuticals over attempt to make generic Evista (Law360)

Femcon Fe (Norethindrone, Ethinyl estradiol, Ferrous fumarate) – Warner Chilcott and Watson resolve patent litigation related to Loestrin 24 and Femcon Fe (Patent Docs)

Glazide (Gliclazidium) – Poland: District Administrative Court of Warsaw allows ‘Glazide’ mark finding Glazide differs from Gliclazidium (Class 46)

K-Dur (Potassium chloride) – US: Special Master says K-Dur reverse payment involving Schering-Plough and Upsher-Smith was legal (Law360)

Lexapro (Escitalopram) – US: Judge rejects Forest Laboratories’ second bid to dismiss Caraco Pharmaceutical Laboratories’ declaratory actions over Lexapro (Law360)

Loestrin 24 (Norethindrone, Ethinyl estradiol, Ferrous fumarate) – Warner Chilcott and Watson resolve patent litigation related to Loestrin 24 and Femcon Fe (Patent Docs)

Lovenox (Enoxaparin) – US: Aventis asks Supreme Court to weigh in on inequitable conduct ruling (Law360)

Pataday, Patanol (Olopatadine) – US: Alcon files patent infringement suits against Apotex and Sandoz over Pataday and Patanol eyedrops (Law360)

Soliris (Eculizumab) – US: PDL BioPharma and Alexion Pharma resolve patent dispute over Soliris (Patent Docs)

Xopenex (Levosalbutamol) – US: Federal judge refuses to dismiss Dey’s declaratory action suit against Sepracor over Xopenex after finding controversy remained despite Sepracor’s promise not to sue (Law360)